Innate and Adaptive Immunity in HPV Pathogenesis and Treatment
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 220
Special Issue Editor
Special Issue Information
Dear Colleagues,
Human papillomavirus (HPV) is one of the most commonly transmitted viruses, and it causes a variety of malignancies, including cervical cancer. HPV infection can stimulate the host immune system (innate immunity and adaptive immunity) to produce a certain immune response; HPV also evades detection and clearance by the host immune system through a variety of immune escape mechanisms. The interaction between HPV and the host immune system determines the different clinical manifestations of HPV infection (clinically asymptomatic lesions persisting or becoming cancerous).
Many clinical and laboratory studies are known to have been conducted to develop effective and specific vaccines against HPV infection and related diseases. Because the immunological basis of HPV infection and related disease progression is unclear, a greater understanding of immune escape mechanisms and the molecular biology of the disease will help in the development of effective vaccines. Therefore, this Special Issue hopes to combine the latest research progress at home and abroad to review the clinical and epidemiological biology, immunology, vaccinology, and other aspects of the pathogenesis of HPV and related diseases.
This Special Issue welcomes articles, reviews, and opinions from scholars around the world on the pathogenesis of HPV, disease prevention and control, and disease treatment, especially autogenous and adaptive immunity.
Dr. Claudia Pinacchio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HPV
- immune
- vaccinology
- biology
- clinical
- epidemic
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.